Abstract: A method of detecting a target sequence is provided, the method comprising: hybridizing an oligonucleotide probe with a nucleic acid present in a test sample, wherein the oligonucleotide probe has a hybridization sequence with respect to a target sequence of the nucleic acid and has at least one covalent bonding group that is crosslinkable with a target base in the target sequence by light irradiation, thereby forming an authentic hybridization product; irradiating light to the test sample after the hybridizing, wherein the covalent bonding group and the target sequence are crosslinked, thereby forming the authentic cross-liked hybridization product having a crosslinked structure; and denaturating the test sample by applying a denaturating condition in which the authentic crosslinked hybridization product is able to be maintained and a non-specific hybridization product is able to be dissociated and separating the oligonucleotide probe derived from the non-specific hybridization product.

Abstract: The present invention provides HIDE1 as novel monocyte markers. Since HIDE1 are membrane proteins, monocytes can be specifically detected by using antibodies that bind to HIDE1. Further, HIDE1-positive monocytes can also be collected from peripheral blood or the like using a cell sorter, magnet, or such. Monocytes that can be prepared based on the present invention are useful in cell immunotherapy.

Abstract: A search was conducted for functional antibodies that endogenously regulate cytokines, focusing on the relationship between inflammatory diseases and cytokines. Mice were immunized with a human peripheral blood monocyte fraction and the obtained antibodies were examined for a cytokine-regulating effect. As a result, of these antibodies, antibody #33 was confirmed to inhibit the production of numerous typical inflammatory cytokines. When, at the same time, the promoting effect of antibody #33 on IL-10 production was examined, it was revealed that antibody #33 has an effect of accelerating IL-10 production but no activity to induce an excessive IL-10 production. The antigen of this promising antibody was verified to be CD61. Therefore, it is conceivable that when anti-CD61 antibodies are applied to the treatment of inflammatory diseases, they would become pharmaceuticals with both a definite efficacy and a high safety.